PodParley PodParley
Let's Talk Risk! with Dr. Naveen Agarwal cover art

All Episodes

Let's Talk Risk! with Dr. Naveen Agarwal — 161 episodes

#
Title
1

Case Study: How Patient Preference Data Rescued a High-Risk Device

2

LTR 150: Jonathan Kendler on Rethinking Human Factors Engineering for AI/ML-Enabled Devices

3

LTR 149: Lavanya Ramnath on Risk Analysis, IDE Strategy, and Patient-Centered Design

4

LTR 148: Chris Daly on Companion Diagnostics, AI, and FDA’s Evolving Approach

5

LTR 147: Richard Matt on Bringing Benefit–Risk Upstream in Design and Development

6

LTR 146: Ganesh Sabat on Scaling MedTech Through Quality

7

LTR 145: Holly Cotter on Avoiding the QMSR Scramble with Smart Quality Planning

8

LTR 144: Jean Blom on How Hazard-First Thinking Improves Risk Management

9

LTR 143: Jennifer Mascioli-Tudor on Leading Proactive Quality in the QMSR Era

10

LTR 142: Florian Tolkmitt on Clinical Evaluation, Risk, and the New ISO Draft Standard

11

LTR 141: Ashkon Rasooli on Applying an Agile Mindset to Risk-Based Quality Systems Under QMSR

12

LTR 140: Pujitha Gourabathini on Connecting Risk Management and Design Controls

13

LTR 139: Steve Silverman on FDA Readiness for QMSR

14

LTR 138: Michelle Lott on QMSR Readiness, Risk-Based Assurance and FDA Expectations

15

LTR 137: Priya Setty on QMSR, Risk-Based Assurance, and Building a Future-Ready RA Career

16

LTR 136: Adam Isaacs Rae on What QMSR Really Changes and What It Doesn't

17

LTR 135: Allison Komiyama on Rethinking Benefit-Risk in MedTech

18

LTR 134: James Pink on Responsible AI and Future of MedTech Safety

19

LTR 133: Megan Kane on Leading QMSR Readiness in MedTech Startups

20

LTR 132: Bijan Elahi on Future of MedTech Safety and the 2026 Conference in Boston

21

LTR 131: Rick Wedge on the Human Side of Safety Risk Management

22

LTR 130: Hannah Walter on Human Factors and Inclusive Design in Medical Devices

23

LTR 129: Viral Thakkar on breakthrough innovation and the Lungpacer story

24

Case Study: The WATCHMAN TruSeal Recall and the Hidden Risk of Procedural Variation

25

LTR 128: Edward Ball on AI, Vigilance and Future of MedTech Regulation

26

LTR 127: Ajay Dankar on Proactive AI Governance in MedTech

27

FDA CSA Debate: Streamlined Assurance or Audit Ambiguity?

28

LTR 126: Adam Foresman on Proactive Compliance and Future of MedTech

29

LTR 125: Kevin Schawinski on Building Trustworthy AI and MedTech Readiness

30

Case Study: Comparing EU and FDA Cybersecurity Guidance for Medical Devices

31

LTR 124: Omar Al Kalaa on Wireless Coexistence and Risk in Connected Medical Devices

32

LTR 123: Richard Matt on Effective Risk Communication

33

Case Study: What AI/ML Device Recalls Reveal About Emerging Risks

34

LTR 122: Tibor Zechmeister on PSUR Best Practices

35

LTR 121: Michelle Lott on Risk, CAPA and FDA Inspections under QMSR

36

Case Study: Contrasting U.S. and EU Approaches to AI Regulation

37

LTR 120: Atty Chakraborty on India's Rising MedTech Sector

38

LTR 119: AI, Risk and Regulatory Strategy with Dr. Jay Vaishnav

39

Case Study: When Clues to a Future Recall Hide in Plain Sight

40

LTR 118: Off-Label Use with Kristen Petersen

41

LTR 117: Queenita Fernandes on Smart Use of AI for Clinical Evaluation

42

A Quick Primer on FDA's Final Guidance for Cybersecurity in Medical Devices

43

LTR 116: Priyanka Murawala on ISO 10993 Update, Biocompatibility, Learning from Recalls

44

LTR 115: Startup Lessons from EU MedTech Shark Tank

45

LTR 114: What QA/RA Professionals Need to Know About Rapidly Growing MedTech in India

46

Case Study: When Underestimating Risk Leads to a Warning Letter

47

LTR 113: Highlights from the International Medical Device Safety Risk Management Conference

48

LTR 112: Overcoming organizational barriers to risk management through collaboration

49

LTR 111: How to sustain and grow a community of practice in risk management

50

Case Study: A Warning Letter Exposes Issues in Risk Analysis

51

LTR 110: Focusing on reliability to build safe medical devices

52

Case Study: A Promising Device Fails in the Market Due to Usability Issues

53

LTR 109: Focus on risk, not just testing, for biocompatibility of medical devices

54

LTR 108: Databases and automation tools for clinical evaluation

55

LTR 107: A 3-step approach to developing secure medical devices

56

LTR 106: Critical role of Medical Safety in device risk management

57

LTR 105: AI-based virtual auditors are coming to MedTech

58

LTR 102: Collaboration that drives innovation, not delays

59

LTR 104: Navigating the regulatory landscape for SaMD in India

60

LTR 103: Start treating human factors as a science, not an art

61

Subatack Live: Navigating the chaos at FDA

62

LTR 101: Power up your career with mentoring

63

Substack Live: Let’s talk about cyber risk in MedTech!

64

LTR 100: What we will need to lead in the age of AI

65

LTR 99: An exciting growth opportunity for MedTech in India

66

Substack Live: How will tariffs affect pharma and med device supply chains

67

LTR 98: Critical role of medical safety officer in medical devices

68

LTR 97: Surviving chaos and uncertainty at the FDA

69

LTR 96: A patient-centric approach to medical device R&D

70

LTR 95: The case for software risk management in AI-driven home health devices

71

LTR 82: Tips for Regulatory Success with AI Devices in Radiology

72

LTR 94: The road ahead for PCCPs and AI/ML amidst chaos at the FDA

73

LTR 93: AI use cases in MedTech regulatory applications

74

LTR 92: Understanding the notified body perspective on clinical evaluation

75

LTR 91: International conference on medical device safety risk management

76

LTR 90: Lead with empathy to grow your Quality career

77

LTR 89: Navigating uncertain times at the FDA

78

LTR 88: Decoding Privacy Laws in Clinical Research

79

LTR 87: A Strategic Approach to Regulatory Success with GenAI Devices

80

LTR 86: Managing Post-Market Design Changes

81

LTR 85: The problem with CAPA problem statements

82

LTR 84: Think of human factors for AI as levels of automation

83

LTR 83: Road to market for AI devices in the EU just got more complex

84

LTR 81: 4 key themes in risk management and an upcoming conference

85

LTR 80: Building safety by design into medical devices

86

LTR 79: Tips for SaMD development and success with FDA

87

LTR 73: It's time to up our game on medical device cybersecurity

88

LTR 78: New challenges in managing risks of software in IVDs

89

PCCP: Opportunity for risk practitioners to shine

90

LTR 77: How GenAI is transforming Quality in MedTech

91

EU vs. FDA: Aligned but different in their approach to safety of AI/ML devices

92

LTR 76: Challenges and opportunities of AI/ML in MedTech

93

LTR 70: Best practices for applying usability engineering to medical devices

94

LTR 74: AR/VR devices in MedTech

95

LTR 72: A clinician's insights on risk and collaboration in MedTech

96

LTR 64: Opportunities and challenges to leverage PCCP for speed to market

97

LTR 71: Medical device cybersecurity now more critical than ever

98

LTR 69: A quick update on the 4th edition of IEC 60601

99

LTR 68: Tips for making customer-focused decisions

100

LTR 67: 3 pillars for defining your IVD risk management strategy

101

LTR 66: Understanding human factors aspect of augmented reality applications in medical devices

102

LTR 65: Demystifying risk-based approach vs. risk management

103

LTR 63: A lawyer's perspective on the QMSR transition

104

LTR 62: Overcoming barriers to cross-functional communication and collaboration

105

LTR 61: Treat human factors as a driver of customer satisfaction, not a check-the-box activity

106

LTR 60: Defining state of the art can be challenging; here are a few tips.

107

LTR 59: FDA's pre-sub program and how it can accelerate medical device innovation

108

LTR 58: Tips for clinicians transitioning into a medical safety role in MedTech

109

LTR 57: It's time to focus on supply chain resiliency not just supplier management

110

LTR 56: How to communicate effectively with senior management

111

LTR 54: Start your risk analysis by first defining the intended use

112

LTR 53: Three big trends to watch in MedTech

113

LTR 52: The key to success as a risk practitioner in the medical device industry.

114

LTR 50: Humility is the key to startup success

115

RM roundup #3: 10 noteworthy risk-related LinkedIn posts

116

LTR 49: A clinician's view on AI/ML enabled medical devices

117

LTR 48: Integrating purchasing controls across product lifecycle

118

LTR 46: Tips to boost effectiveness of medical device post-market surveillance

119

LTR Weekly Digest #31 - 6th April, 2024

120

LTR 45: A patient's perspective on CGMs

121

LTR 44: Why we need a new approach to learning medical software and medical AI

122

RM roundup #2: 10 noteworthy risk-related LinkedIn posts

123

LTR 43: Tips for integrating risk analysis with design controls

124

RM roundup #1: 10 of my favorite risk-related LinkedIn posts

125

LTR 42: State or event? Thinking clearly about hazards will help you manage risk.

126

LTR 40: A guest podcast with NAMSA - Part 1

127

LTR 39: Overcoming challenges in linking risk management with design controls

128

LTR 38: How medical safety professionals can serve as culture brokers in MedTech

129

LTR 36: Why we should not overlook the quality-of-life benefit in risk evaluation

130

LTR Weekly Digest #19 - 13th January, 2024

131

LTR 35: Tips for improving collaboration in risk management

132

LTR Weekly Digest #18 - 6th January, 2024

133

LTR 34: Build a culture of Quality to achieve inspection-readiness at all times

134

LTR 33: AI and the future of work for QA/RA professionals

135

LTR 32: A new paradigm for building connected medical devices

136

LTR 31: Focus on the purpose to measure process effectiveness

137

LTR 30: It is time to unfake risk management!

138

LTR 29: Challenges and opportunities for digital technologies in medical applications

139

LTR 28: It is time to build equity in medical device design control

140

LTR 27: Practicable or not, that's the question for risk control

141

LTR 26: Seek clinical input early in development to achieve market success later

142

LTR 25: Career tip - learn to effectively communicate regulatory risk in business terms

143

LTR 24: Clinical evaluation is a lifecycle process, not a one-time activity

144

LTR 23: Focus on intended use in the clinical environment for risk management of IVDs

145

Ep 22: Think of post-market surveillance as a value adding business process

146

Ep 21: Why risk practitioners must build the empathy muscle

147

Ep 20: Team diversity helps boost competence in risk management

148

Ep 19: How QA/RA professionals can help drive innovation in AI/ML

149

Ep 18: Risk based approach to building a QMS in a startup

150

Ep 17: Risk management lessons learned from running the Boston marathon

151

Ep 16: Clinical evaluation is now more important than ever under EU-MDR

152

Ep 15: Collaboration is the secret sauce for success in risk management

153

LTR14: The most important question for risk management: who is taking the risk?

154

Ep 13: Compliance: an obstacle or an opportunity?

155

LTR12: Risk lessons learned from working on a hydrogen-powered car

156

Ep 11: Understanding a physician's view on risk

157

LTR 10: Safety is important, but not the only objective for risk management

158

Ep 09: Tips for a risk-based approach to auditing Quality Systems

159

Ep 08: Understanding the interface between clinical evaluation and risk management

160

Ep 07: Risk management of IVDs requires a different approach

161

Best practices for using FMEAs for medical devices